Benefit of Bet v 1 contiguous overlapping peptide

Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season Alexander Kettner, Ph. D, Gilles Della. Corte, MD, Fréderic de Blay, MD, Ph. D, Lars Jacobsen, Ph. D, Marek Jutel, MD, Margitta Worm, MD, Vincent Charlon, Ph. D, Kim Simonsen, MD, Christophe Reymond, Ph. D, François Spertini, MD Journal of Allergy and Clinical Immunology Volume 142 Issue 2 Pages 678 -680. e 7 (August 2018) DOI: 10. 1016/j. jaci. 2018. 01. 052 Copyright © 2018 Terms and Conditions

Fig 1 Journal of Allergy and Clinical Immunology 2018 142678 -680. e 7 DOI: (10. 1016/j. jaci. 2018. 01. 052) Copyright © 2018 Terms and Conditions

Fig 2 Journal of Allergy and Clinical Immunology 2018 142678 -680. e 7 DOI: (10. 1016/j. jaci. 2018. 01. 052) Copyright © 2018 Terms and Conditions

Fig E 1 Journal of Allergy and Clinical Immunology 2018 142678 -680. e 7 DOI: (10. 1016/j. jaci. 2018. 01. 052) Copyright © 2018 Terms and Conditions

Fig E 2 Journal of Allergy and Clinical Immunology 2018 142678 -680. e 7 DOI: (10. 1016/j. jaci. 2018. 01. 052) Copyright © 2018 Terms and Conditions

Fig E 3 Journal of Allergy and Clinical Immunology 2018 142678 -680. e 7 DOI: (10. 1016/j. jaci. 2018. 01. 052) Copyright © 2018 Terms and Conditions

Fig E 4 Journal of Allergy and Clinical Immunology 2018 142678 -680. e 7 DOI: (10. 1016/j. jaci. 2018. 01. 052) Copyright © 2018 Terms and Conditions